| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/02/2006 | US20060025416 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| 02/02/2006 | US20060025415 Compositions useful as inhibitors of voltage-gated sodium channels |
| 02/02/2006 | US20060025414 Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 02/02/2006 | US20060025413 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 02/02/2006 | US20060025412 Enzyme inhibitors as bactericides for infections |
| 02/02/2006 | US20060025411 Methods for treating diseases or conditions using dihydropteridinone compounds |
| 02/02/2006 | US20060025410 2,4-Pyrimidinediamine compounds and their uses |
| 02/02/2006 | US20060025409 e.g. N-{2-[3-(3,4-dimethoxy-phenyl)-propyl]-6-morpholin-4-yl-pyrimidin-4-yl}-N'-(1H-indol-3-ylmethylene)-hydrazine; interleukin-12 antagonist; antiinflammatory, antidiabetic agent; rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus |
| 02/02/2006 | US20060025408 Process for the preparation of crystalline form-1 of 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide |
| 02/02/2006 | US20060025407 Succinoylaminobenzodiazepines as inhibitors of Abeta protein production |
| 02/02/2006 | US20060025406 Modulators of hepatocyte growth factor/c- Met activity |
| 02/02/2006 | US20060025405 1-Methyl,2,6-dioxo,4-(4-(ethyloxycarbony)piperazin-1-yl-),5-(3-trifluoromethylphenyl)methyl-)-1,2,3,6-tetrahydropyrimidine; antagonist, antagonism; psychoses; antidepressants; schizophrenia; psychological disorders; Alzheimer's disease; neurodegenerative diseases;drug abuse, drug dependence (cocaine) |
| 02/02/2006 | US20060025404 Such as 1-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-4-{[4-(methylsulfonyl)phenyl]carbonyl}piperazine; neurodegenerative disorders including Alzheimer's disease; allergic rhinitis |
| 02/02/2006 | US20060025403 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 02/02/2006 | US20060025402 Benzimidazolidinone derivatives as muscarinic agents |
| 02/02/2006 | US20060025401 Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders |
| 02/02/2006 | US20060025400 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use |
| 02/02/2006 | US20060025399 Crystalline anhydrous cefdinir and crystalline cefdinir hydrates |
| 02/02/2006 | US20060025398 Topical antiviral therapeutic and prophylactic treatment of adenoviruses and their associated diseases |
| 02/02/2006 | US20060025397 Method of resistance of epilepsy by suppressing the function of alpha 1g protein |
| 02/02/2006 | US20060025396 Isophthalic acid derivatives as matrix metalloproteinase inhibitors |
| 02/02/2006 | US20060025395 Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof |
| 02/02/2006 | US20060025394 Estradiol-related compounds and methods of use as anti-tumor agents |
| 02/02/2006 | US20060025393 Steroid derivatives |
| 02/02/2006 | US20060025392 Combination medicament |
| 02/02/2006 | US20060025391 Combination of azelastine and steroids |
| 02/02/2006 | US20060025390 Treatment of hormone allergy and related symptoms and disorders |
| 02/02/2006 | US20060025389 Methods of treating fungal infections using lupeol |
| 02/02/2006 | US20060025388 Compositions and methods relating to novel compounds and targets thereof |
| 02/02/2006 | US20060025387 Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
| 02/02/2006 | US20060025386 Method of treatment of retinal ischemia with diazoxide |
| 02/02/2006 | US20060025385 L-DOPA amide derivatives and uses thereof |
| 02/02/2006 | US20060025384 adding organic solvent and dissolivng adefovir dipivoxil ultrasonically to form solution, and spray drying; have different melting points, solubility, and density |
| 02/02/2006 | US20060025383 Aminobenzoxazoles as therapeutic agents |
| 02/02/2006 | US20060025382 Use of a crosslinked or inhibited starch product |
| 02/02/2006 | US20060025381 Use of a chemically modified starch product |
| 02/02/2006 | US20060025380 Formulations for non-parenteral use including hydrophobic cyclodextrins |
| 02/02/2006 | US20060025379 polysaccharides; packages |
| 02/02/2006 | US20060025378 Dose dependent elimination of HA and cell receptor stimulation |
| 02/02/2006 | US20060025377 Inhibitor of angiogenesis and kit for treating cancer comprising the inhibitor |
| 02/02/2006 | US20060025376 Uridine effects on dopamine release |
| 02/02/2006 | US20060025375 2'-deoxy- beta -L-erythro-pentofuranonucleosides to those already infected with hepatits B; can be coadministered with 3TC, FTC, L-FMAU, DAPD, famciclovir, penciclovir, BMS-200475, adefovir, lobucavir, ganciclovir, or ribavarin |
| 02/02/2006 | US20060025374 Novel oligoribonucleotide derivatives for specific inhibition of gene expression |
| 02/02/2006 | US20060025363 Use of antisense oligonucleotides for the treatment of degenerative skin conditions |
| 02/02/2006 | US20060025362 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation |
| 02/02/2006 | US20060025360 Human cervical cancer protooncogene and protein encoded therein |
| 02/02/2006 | US20060025359 Orally or parenterally administering an adenosine deaminase inhibitor selected from pentostatin, fludarabine monophosphate, and cladribine; steroid-refractory acute and chronic GVHD |
| 02/02/2006 | US20060025358 Treatment and Prevention of Th1 and 'Autoimmune' Diseases Effected with Antibiotics and/or Angiotensin Inhibition |
| 02/02/2006 | US20060025357 Use of agent for suppressing infection and proliferation of human immunodeficiency syndrome virus |
| 02/02/2006 | US20060025356 28-epirapalogs |
| 02/02/2006 | US20060025355 Compositions comprising amphotericin B, methods, and systems |
| 02/02/2006 | US20060025354 using anthocyanins, anthocyanidins, ursolic acid and/or betulinic acid; cyanidin-3-glycoside, delphinidin-3-galactoside, pelargonidin-3-galactoside |
| 02/02/2006 | US20060025353 increasing insulin concentration secreted by pancreatic beta cells by providing to cells in the presence of glucose at a glucose concentration between a normal human glucose level and an elevated human glucose level of 2.5 times the normal human glucose level an anthocyanin or anthocyanidin |
| 02/02/2006 | US20060025352 Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
| 02/02/2006 | US20060025351 Heterocyclic alcohols such as 2-deoxy-D-glucose or 5-thio-D-glucose, used as anticarcinogenic agents or angiogenesis inhibitors; glycolysis antagonists |
| 02/02/2006 | US20060025350 4-hydroxy-2-hydroxymethyl-pyrrolidin-3-yl 4-O-(6-deoxy- alpha -D-glucopyranosyl)- alpha -D-glucopyranoside; alpha-amylase inhibitor; antidiabetic agents, hypoglycemic agents; side effect reduction |
| 02/02/2006 | US20060025349 D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture |
| 02/02/2006 | US20060025344 Ghrelin receptor inverse agonists for regulation of feeding behaviors |
| 02/02/2006 | US20060025343 Angiogenically effective unit dose fo FGF and method of adminstering |
| 02/02/2006 | US20060025334 Vanilloid receptor-2 ligands for treating anxiety or depression |
| 02/02/2006 | US20060025333 Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| 02/02/2006 | US20060024820 Chromosome-based platforms |
| 02/02/2006 | US20060024754 Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 02/02/2006 | US20060024727 Antisense modulation of C-reactive protein expression |
| 02/02/2006 | US20060024691 Novel pathways in the etiology of cancer |
| 02/02/2006 | US20060024683 Transcription factor of MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances |
| 02/02/2006 | US20060024664 Characterizing purity and activity of polysaccharide preparations including glycosaminoglycans such as heparin |
| 02/02/2006 | US20060024659 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| 02/02/2006 | US20060024397 fruit extracts containing anthocyanins |
| 02/02/2006 | US20060024393 Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases |
| 02/02/2006 | US20060024392 Compositions and methods for enhancing the effectiveness of a chemotherapeutic agent |
| 02/02/2006 | US20060024389 Plant derived or derivable material with appetite suppressing activity |
| 02/02/2006 | US20060024388 Plant derived or derivable material with appetite suppressing activity |
| 02/02/2006 | US20060024384 Compositions and methods for nutrition supplementation |
| 02/02/2006 | US20060024383 Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses |
| 02/02/2006 | US20060024381 Composition comprising particulate zinc material with a high relative zinc lability |
| 02/02/2006 | US20060024376 Methods and compositions for reducing toxicity associated with leflunomide treatment |
| 02/02/2006 | US20060024374 Pharmaceutical compositions suitable for the treatment of ophthalmic diseases |
| 02/02/2006 | US20060024372 High viscosity antibacterials |
| 02/02/2006 | US20060024367 Controlled release alpha lipoic acid formulation with an inositol compound |
| 02/02/2006 | US20060024365 Novel dosage form |
| 02/02/2006 | US20060024364 Directly compressible formulations of azithromycin |
| 02/02/2006 | US20060024363 Directly compressible formulations of azithromycin |
| 02/02/2006 | US20060024362 Composition comprising a benzimidazole and process for its manufacture |
| 02/02/2006 | US20060024361 Disintegrant assisted controlled release technology |
| 02/02/2006 | US20060024360 Stable injectable composition of alpha tocopheryl succinate, analogues and salts thereof |
| 02/02/2006 | US20060024356 Canine osteoarthritis diet formulation |
| 02/02/2006 | US20060024353 Novel porous film-forming granules, process for their preparation and application in the film coating of tablets and sweets |
| 02/02/2006 | US20060024352 Phytosterol nutritional supplements |
| 02/02/2006 | US20060024345 Pediculicidal and ovacidal treatment compositions and methods for killing head lice and their eggs |
| 02/02/2006 | US20060024336 Ion binding compositions |
| 02/02/2006 | US20060024330 Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| 02/02/2006 | US20060024329 Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2. |
| 02/02/2006 | US20060024315 Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| 02/02/2006 | US20060024299 Human osteoclast derived cathepsin |
| 02/02/2006 | US20060024293 Antibody for use in the treatment and prevention of sepsis, infections, autoimmune and graft-versus-host diseases; biodegradable, biocompatible polymer and human antibody, or an antigen-binding portion thereof, that dissociates from human TNF alpha |
| 02/02/2006 | US20060024284 Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| 02/02/2006 | US20060024283 Red blood cells loaded with S-nitrosothiol and uses therefor |
| 02/02/2006 | US20060024277 Method of skin care and/or treatment using extracts enriched in mitochondria |
| 02/02/2006 | US20060024275 Methods for use of MPL ligands with primitive human stem cells |